3 results
Approved WMOCompleted
To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.
Approved WMORecruiting
Objective is to compare field inhomogeinity between conventional titanium osteosynthesis and CFR-PEEK osteosynthesis on MR imaging. Visualisation of regions of interest will be scored and volume of field inhomogeneity will be calculated.
Approved WMOPending
Primary Objective• Evaluate the efficacy of loncastuximab tesirine combined with rituximab compared to standard immunochemotherapy Secondary Objectives• Further evaluate the efficacy of loncastuximab tesirine combined with rituximab compared to…